Immunocore to present at upcoming investor conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Immunocore (Nasdaq: IMCR) announced management will present at two investor conferences in November 2025: a Guggenheim 2nd Annual Healthcare Innovation Conference fireside chat on Tuesday, November 11, 2025 at 3:00 p.m. EST, and a Jefferies London Healthcare Conference fireside chat on Wednesday, November 19, 2025 at 3:30 p.m. GMT.
Where relevant, presentations will be webcast live and available under Investors > Events & Presentations on Immunocore's website, with replays posted for a limited time.
Details
News Market Reaction – IMCR
On Nov 10, the day this news came out, IMCR closed 4.48% above the previous close.
Data tracked by StockTitan Argus for the Nov 10 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
(OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & GAITHERSBURG, Md., US, November 10, 2025) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” or the “Company”), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve outcomes for patients with cancer, infectious diseases and autoimmune diseases, today announced management will participate at the following conferences in November.
Guggenheim 2nd Annual Healthcare Innovation Conference
Fireside Chat: Tuesday, November 11, 2025, at 3:00 p.m. EST
Jefferies London Healthcare Conference
Fireside Chat: Wednesday, November 19, 2025, at 3:30 p.m. GMT
Where relevant, the presentations will be webcast live and can be accessed by visiting ‘Events & Presentations’, under ‘Events’, via the ‘Investors’ section of Immunocore’s website at www.immunocore.com. Following the event, a replay of the presentations will be made available for a limited time.
About Immunocore
Immunocore is a commercial-stage biotechnology company pioneering the development of a novel class of TCR bispecific immunotherapies called ImmTAX – Immune mobilizing monoclonal TCRs Against X disease – designed to treat a broad range of diseases, including cancer, autoimmune diseases and infectious diseases. Leveraging its proprietary, flexible, off-the-shelf ImmTAX platform, Immunocore is developing a deep pipeline in multiple therapeutic areas, including numerous active clinical and pre-clinical programs in oncology, infectious diseases, and autoimmune diseases. The Company’s most advanced oncology TCR therapeutic, KIMMTRAK, has been approved for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma in the United States, European Union, Canada, Australia, and the United Kingdom.
Contact Information
Immunocore
Sébastien Desprez, VP Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Follow Immunocore on LinkedIn: @Immunocore
Investor Relations
Clayton Robertson / Morgan Warenius
T: +1 (215) 384-4781
E: ir@immunocore.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.